Cargando…
Treatment with the direct oral anticoagulants (DOACs) apixaban and rivaroxaban associated with significant worsening of behavioural and psychological symptoms of dementia (BPSD)
We report the cases of two patients who developed worsening behavioural and psychological symptoms of dementia (BPSD), coinciding with starting the factor Xa inhibitor direct oral anticoagulant medications apixaban and rivaroxaban, respectively. Both patients required detaining under the Mental Heal...
Autores principales: | Porter, Kim Maria Frances, Hargreaves, Iain Parry, De Souza, Stephen, Goddard, Rebecca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7942237/ https://www.ncbi.nlm.nih.gov/pubmed/33685912 http://dx.doi.org/10.1136/bcr-2020-240059 |
Ejemplares similares
-
Treatment with the direct oral anticoagulants (DOACs) Apixaban and Rivaroxaban associated with significant worsening of behavioural and psychological symptoms of dementia (BPSD)
por: Porter, Kim, et al.
Publicado: (2021) -
DOACs in Valvular Heart Disease: Latest Key Updates on PROACT Xa
(Apixaban) and INVICTUS (Rivaroxaban)
por: Ryu, Rachel
Publicado: (2022) -
Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the
Residual Activity of Dabigatran, Rivaroxaban, and Apixaban
por: Slavik, L., et al.
Publicado: (2019) -
Developing Inpatient Management Strategies for Behavioural and Psychological Symptoms of Dementia (DIMS-BPSD)
por: Parker, Jennifer, et al.
Publicado: (2022) -
Assessment of DOAC in GEriatrics (
Adage
Study): Rivaroxaban/Apixaban Concentrations and Thrombin Generation Profiles in NVAF Very Elderly Patients
por: Foulon-Pinto, Geoffrey, et al.
Publicado: (2023)